



The Global Dermatology Market to 2026

Pharmaceutical, Commercial and Strategic Developments in the Global Dermatology Market 2016-2026



The Global Dermatology Market to 2026

Pharmaceutical, commercial and strategic developments in the global dermatology market 2016-2026

Chapter 1 - Executive Summary

- 1.1 Executive Summary
- 1.2 Report Description
- 1.3 Market Segmentation
- 1.4 Research Methodology

Chapter 2 - Introduction to Dermatological Diseases and Prescription Treatments

- 2.1 Structure and function of human skin
- 2.2 Dermatological conditions and skin disorders
 - 2.2.1 Acne vulgaris
 - 2.2.1.1 Types and symptoms of acne vulgaris
 - 2.2.1.2 Current prescription (rx) treatments for acne vulgaris
 - 2.2.2 Dermatitis
 - 2.2.2.1 Types and symptoms of dermatitis
 - 2.2.2.2 Current prescription (rx) treatments for dermatitis
 - 2.2.3 Psoriasis
 - 2.2.3.1 Types and symptoms of psoriasis
 - 2.2.3.2 Current prescription (rx) treatments for psoriasis
 - 2.2.4 Skin cancer
 - 2.2.4.1 Types and symptoms of skin cancer
 - 2.2.4.2 Current prescription (rx) treatments for skin cancer
 - 2.2.5 Skin infections
 - 2.2.5.1 Types and symptoms of skin infections
 - 2.2.5.2 Current prescription (rx) treatments for skin infections
 - 2.2.6 Rosacea
 - 2.2.6.1 Types and symptoms of rosacea
 - 2.2.6.2 Current prescription (rx) treatments for rosacea
 - 2.2.7 Alopecia
 - 2.2.7.1 Types and symptoms of alopecia
 - 2.2.7.2 Current prescription (rx) treatments for alopecia

Chapter 3 - Current trends and developments in the global dermatology market

3.1 Current trends, challenges and developments

3.2 Mergers and Acquisitions

Chapter 4 - Global dermatological drugs market and forecast 2016 - 2026

4.1 Global acne vulgaris market, 2016 - 2026

4.1.1 Key trends in the global acne vulgaris market

4.1.2 Market size and forecast

4.1.3 Major drugs and forecast

4.1.3.1 Solodyn market and forecast

4.1.3.2 Doryx market and forecast

4.1.3.3 Epiduo market and forecast

4.1.4 Acne vulgaris - phase iii drugs pipeline forecast

4.1.4.1 Onexton (valeant)

4.1.4.2 Epiduo forte (galderma)

4.1.4.3 Sarecycline (actavis)

4.1.5 Acne vulgaris - phase ii drugs pipeline forecast

4.1.5.1 Drm01 (dermira)

4.1.5.2 Fmx101 (foamix)

4.1.5.3 Sb204 (novan therapeutics)

4.1.5.4 Sebo02 (sebacia)

4.1.5.5 Mtc896 (mimetica)

4.2 Global psoriasis market, 2016 - 2026

4.2.1 Key trends in the global psoriasis market

4.2.2 Market size and forecast

4.2.3 Major drugs and forecast

4.2.3.1 Stelara (psoriasis) market and forecast

4.2.3.2 Enbrel (psoriasis) market and forecast

4.2.3.3 Humira (psoriasis) market and forecast

4.2.3.4 Otezla (psoriasis) market and forecast

4.2.3.5 Cosentyx (psoriasis) market and forecast

- 4.2.3.6. Taltz (psoriasis) market and forecast
- 4.2.3.7. Piclidenoson (psoriasis) market and forecast
- 4.2.4. Psoriasis - phase iii drugs (injectable biologics) pipeline forecast
 - 4.2.4.1. Bi 655066 (boehringer ingelheim)
 - 4.2.4.2. Guselkumab (janssen)
 - 4.2.4.3. Tildrakizumab (sun pharma)
- 4.2.5. Psoriasis - phase iii drugs (injectable biologics) pipeline forecast
 - 4.2.5.1. Cimzia (ubc)
 - 4.2.5.2. Brodalumab (astra-zeneca/valeant)
- 4.2.6. Psoriasis - phase ii drugs (injectable biologics) pipeline forecast
 - 4.2.6.1. Tregalizumab (biotest ag)
 - 4.2.6.2. Namilumab (takeda pharmaceuticals)
 - 4.2.6.3. Imo-8400 (idera pharmaceuticals)
- 4.2.7. Psoriasis - phase ii (10) drugs (orally administered) pipeline forecast

4.3 Global alopecia market, 2016 - 2026

- 4.3.1. Key trends in the global alopecia market
- 4.3.2. Market size and forecast
- 4.3.3. Major drugs and forecast
 - 4.3.3.1. Propecia market and forecast
- 4.3.4. Alopecia - phase iii drugs pipeline forecast
 - 4.3.4.1. Bimatoprost (allergan)
 - 4.3.4.2. Sm04554 (samumed)
- 4.3.5. Alopecia - phase ii (2) drugs pipeline forecast

4.4 Global skin cancer market, 2016 - 2026

- 4.4.1. Key trends in the global skin cancer market
- 4.4.2. Market size and forecast
- 4.4.3. Major drugs and forecast
 - 4.4.3.1. Yervoy market and forecast
 - 4.4.3.2. Zelboraf + cotellic market and forecast
 - 4.4.3.3. Tafinlar + mekinist market and forecast
 - 4.4.3.4. Keytruda market and forecast
 - 4.4.3.5. Opdivo, opdivo + yervoy market and forecast

- 4.4.3.6. Imlygic market and forecast
- 4.4.3.7. Erivedge market and forecast
- 4.4.3.8. Odomzo market and forecast
- 4.4.4. Skin cancer - phase iii (12) drugs pipeline forecast
- 4.4.5. Skin cancer - phase ii (53) drugs pipeline forecast

- 4.5 Global skin infections market, 2016 - 2026
 - 4.5.1. Key trends in the global skin infections market
 - 4.5.2. Market size and forecast
 - 4.5.3. Major drugs and forecast - csssis
 - 4.5.3.1. Cubicin market and forecast
 - 4.5.3.2. Zyvox market and forecast
 - 4.5.3.3. Sivextro market and forecast
 - 4.5.3.4. Orbactiv market and forecast
 - 4.5.3.5. Dalvance market and forecast
 - 4.5.3.6. Tygacil market and forecast
 - 4.5.3.7. Teflaro market and forecast
 - 4.5.4. Major drugs and forecast - onychomycosis
 - 4.5.4.1. Kerydin market and forecast
 - 4.5.4.2. Jublia market and forecast
 - 4.5.5. Skin infections - phase iii (11) drugs (csssis) pipeline forecast
 - 4.5.6. Skin infections - phase iii (3) drugs (onychomycosis) pipeline forecast
 - 4.5.7. Skin infections - phase ii (3) drugs (onychomycosis) pipeline forecast

- 4.6 Global atopic dermatitis market, 2016 - 2026
 - 4.6.1. Key trends in the global atopic dermatitis market
 - 4.6.2. Market size and forecast
 - 4.6.3. Major drugs and forecast
 - 4.6.4. Atopic dermatitis - phase iii drugs pipeline forecast
 - 4.6.4.1. Dupilumab (sanofi/regeneron)
 - 4.6.4.2. Crisaborole (anacor/pfizer)
 - 4.6.4.3. Zpl-389 (ziarco pharma)
 - 4.6.4.4. Nanocyclo (immune pharmaceuticals)
 - 4.6.5. Atopic dermatitis - phase ii drugs (orally/topically administered) pipeline forecast

- 4.6.5.1. Tofactinib/xeljanz (pfizer)
- 4.6.5.2. Zpl-521 (ziarco pharma)
- 4.6.5.3. Opa-15406 (otsuka/medimetriks)
- 4.6.6. Atopic dermatitis - phase ii drugs (injectable moabs) pipeline forecast
 - 4.6.6.1. Bertilimumab (immune pharmaceuticals)
 - 4.6.6.2. Tralokinumab (leo pharma/astra-zeneca)
 - 4.6.6.3. Nemolizumab (chugai pharmaceuticals)
 - 4.6.6.4. Lebrikizumab (roche/genentech)

- 4.7 Global rosacea market, 2016 - 2026
 - 4.7.1. Key trends in the global rosacea market
 - 4.7.2. Market size and forecast
 - 4.7.3. Major drugs and forecast
 - 4.7.3.1. Finacea gel + finacea foam (bayer/foamix)
 - 4.7.3.2. Mirvaso (galderma)
 - 4.7.3.3. Soolantra (galderma)
 - 4.7.3.4. Oracea (galderma)
 - 4.7.4. Rosacea - phase iii drugs pipeline forecast
 - 4.7.4.1. Azultro (allergan)

Chapter 5 - Leading companies in the global dermatology market

- 5.1 Allergan (Allergan plc.)
- 5.2 Galderma (Nestle Skin Health)
- 5.3 Valeant pharmaceuticals
- 5.4 Novartis
- 5.5 Merck & co. inc.
- 5.6 Pierre Fabre

Chapter 6 - Key national markets in the global dermatology sector, 2016 - 2026

- 6.1 US Dermatological Drugs Market and Forecast, 2016 - 2026
- 6.2 UK Dermatological Drugs Market and Forecast, 2016 - 2026
- 6.3 France Dermatological Drugs Market and Forecast, 2016 - 2026
- 6.4 Germany Dermatological Drugs Market and Forecast, 2016 - 2026
- 6.5 Spain Dermatological Drugs Market and Forecast, 2016 - 2026

- 6.6 Italy Dermatological Drugs Market and Forecast, 2016 - 2026
- 6.7 Japan Dermatological Drugs Market and Forecast, 2016 - 2026
- 6.8 Row Dermatological Drugs Market and Forecast, 2016 - 2026

Chapter 7 - Expert opinion

7.1 Bristol-Myers Squibb

7.2 Johnson & Johnson

Appendix: skin cancer - phase iii and phase ii drugs pipeline

2.2 Dermatological Conditions and Skin Disorders

2.2.1.ACNE VULGARIS

2.2.1.1. TYPES AND SYMPTOMS OF ACNE VULGARIS

A skin condition or problem resulting from clogging up of pores due to oil or dead skin cells. There are three major factors causing acne:

- a. Hair follicle blockage that release oil
- b. Oil overproduction due to enlargement of oil glands on the skin
- c. Bacterial growth of Propionibacterium Acnes within the hair follicles

TABLE 1 TYPES AND SYMPTOMS OF ACNE VULGARIS

Type	Symptoms
White Heads	Very small in size, remains under the skin
Black Heads	Black, clearly visible and appears on the surface of skin
Papules	Small usually pink bumps, clearly visible, appears on the surface of skin
Pustules	Red base with pus formation at the tip, clearly visible, appears on the surface of skin
Nodules	Large, solid, painful, clearly visible and embedded in the skin
Cysts	Painful, filled with pus, clearly visible on the surface of skin and causes scars

GMR Data 2016

2.2.1.2. CURRENT PRESCRIPTION (RX) TREATMENTS FOR ACNE VULGARIS

Currently available treatments for Acne Vulgaris can be classified into following:

- a. **Topical:** A type of medicine that can be rubbed into skin. Common topical treatments for mild Acne Vulgaris include:
 - **Benzoyl Peroxide** is an effective agent available in different formulations like gels, lotions and creams. The drug is anti-inflammatory and is indicated in mild-to-moderate Acne Vulgaris.
 - **Topical Retinoids** are 'Vitamin A' derivatives, they work by preventing dead skin cells plugging hair follicles and reducing inflammation. Currently available retinoids are Tretinoin, Adapalene, Tazarotene, Isotretinoin, Metretinide, Retinaldehyde, and β -Retinoyl Glucuronide. They are available in gel or cream form.

Pierre Fabre Dermatology Partnership Deals 2011-2015

Sign Date	Partnering Companies	Product Deal	Deal	Contract Type	Product Name	Indication	Territory/ Countries
December 2014	VINAS (Spain)	Products Deals	IN	Distribution	Molus derm	Molluscum contagiosum	France, Germany, Italy, Greece, Portugal, Netherlands, Norway, Belgium, Czech Rep., Slovak Rep., Poland, Bulgaria, Austria, Romania, Denmark, Finland, Luxembourg, Sweden, Algeria, Morocco, Turkey
March 2014	CATALENT (France)	Products Deals	IN	License & Supply + Territories extension	Curacne (isotretin oine)	Acne	Iran, Iraq
January 2014	UPMC & CNRS (France)	Partner ship	R&D	Common Patents Use	-	-	-
December 2012	MARUHO (Japan)	Products Deals	OUT	Exclusive License	V0400SB	Hemangioma	Japan
April 2012	CATALENT (France)	Products Deals	IN	Development & License	Curacne (isotretin oine) new dosage (30 mg)	Acne	Europe - Latam - Middle East
July 2011	SANOFI AVENTIS (France)	Products Deals	IN	Files acquisition	Batrafen Shampoo	-	France

Pierre Fabre 2016



About GMR Data

Quickly becoming one of the leading business information companies, GMR Data brings together some of the world's leading market researchers to identify, analyse and understand your industry. We then deliver unique commercial reports with in-depth audits, clear market breakdowns, visual appraisals such as tables, graphs, charts, as well as industry surveys, plus enterprise interviews with some of the leading and innovative players in your market. This information is available nowhere else. Only by working with GMR Data can you access tomorrow's information, today.

GMR Data has firmly established itself as the first port-of-call for the industry professional that needs independent, timely and high quality original material to be relied upon. For sample issues or promotional material of GMR Data products please contact us at the address below.

Web: www.GMRData.com

Email: info@GMRData.com